Current trials | Chris O'Brien Lifehouse

Current Recruiting Clinical Trials

If you wish to participate in a clinical trial, speak with your treating oncologist or GP to see if there are current trials you may be suitable for.

If  you cannot find a suitable trial under your specific cancer type, please refer to “Solid Tumours and Phase 1 Studies” for trials including multiple cancer types.

  • TRIAL REFERENCE:  LH19.060 PROOF QBGJ398-301
    SUMMARY: A Phase 3 open label randomised, controlled study of oral infigratinib versus gemcitabine with cisplatin in subjects with advanced/metastatic or ineroperable cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF Trial
    LEAD INVESTIGATOR:Dr Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.009 NUCANA NU TIDE 121
    SUMMARY: A Phase 3 open label multi centre randomised study comparing NUC-1031 plus Cisplatin to Gemcitibine plus Cisplatin in patients with previously untreated locally advanced or metastatic Biliary Tract Cancer
    LEAD INVESTIGATOR:Dr Hao-Wen Sim
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.037 PCR-MIB
    SUMMARY: Clinical Study No. [ANZUP 1502], Phase II study of Pembrolizumab with ChemoRadiotherapy as treatment for muscle invasive bladder cancer protocol
    LEAD INVESTIGATOR: A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.040 THOR
    SUMMARY: Clinical Study JNJ42756493 : a Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene
    LEAD INVESTIGATOR: A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.058 CA209-7G8
    SUMMARY: A Phase 3, Randomized, Double-blind Trial of Nivolumab in Combination with Intravesical BCG versus Standard of Care BCG Alone in Participants with High-risk Non-muscle Invasive Bladder Cancer That Is Persistent or Recurrent After Treatment with BCG
    LEAD INVESTIGATOR:Dr Alison Zhang
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.062 CA209-9UT
    SUMMARY: A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
    LEAD INVESTIGATOR:Dr Alison Zhang
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.041 TROG 15.02 ROAM
    SUMMARY:  Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial (ROAM)
    LEAD INVESTIGATOR:Dr Nitya Patanjali
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.003 NUTMEG
    SUMMARY:  A Randomised Phase II Study of NivIUmab and TeMozolomide alone in newly diagnosed Elderly patients with Glioblastoma (NUTMEG)
    LEAD INVESTIGATOR: Prof John Simes
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.037 MoST Addendum 8-Substudies 19-20
    SUMMARY: Single arm, open label, signal seeking, phase IIa trial of the activity of Trastuzumab emtansine (T-DM1) in patients with tumours harbouring HER2
    amplifications or mutations
    LEAD INVESTIGATOR: Dr Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.029 WinPro
    SUMMARY: An open-label, randomized, window of opportunity study between diagnosis and definite surgery, to assess the effect of antiestrogen therapies, alone and in combination with microionized progesterone (prometrium) in patients with newly diagnosed ER+PR+ breast cancer.
    LEAD INVESTIGATOR: Dr Mun Hui
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.009 MK3475-756
    SUMMARY: A Randomised, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Rick Early Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (Keynote 756
    LEAD INVESTIGATOR: Dr Jane Beith
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.005 WO39391 BIG 16-AFT-27 IMPAssion
    SUMMARY: A Phase 3 multicenter randomised open label study comparing atezolizuzmab (anti PDL1 antibody) in combination with adjuvant anthracycline /taxane based chemotherapy versus chemotherapy alone in patients with operable triple negative breast cancer
    LEAD INVESTIGATOR: Dr Jane Beith
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.026 MK3475-630
    SUMMARY: Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advances Cutaneous Squamous Cell Carcinoma
    LEAD INVESTIGATOR: Dr Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.062 CERPASS REPLIMUNE RPL-002
    SUMMARY: A randomised controlled open label Phase 2 study of cemiplimab as a single agent & in combination with RP1 in patients with Advanced Cutaneous Squamous Cell Carcinoma
    LEAD INVESTIGATOR: Dr Jenny Lee
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.050 CANNABIS
    SUMMARY: CTC0146 : Pilot and definitive randomised double-blind, placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (The CannabisCINV study)
    LEAD INVESTIGATOR: Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH15.055 AG0213CR ASCOLT
    SUMMARY: AG0213CR : Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers. An International, Multi-centre Double Blind, Randomised Placebo Controlled Phase III Trial
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.027 SPAR
    SUMMARY: A randomized, placebo-controlled phase II trial of Simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.010 CSP ISO CC007 ISOFOL
    SUMMARY: A randomised multi centrer parallel group Phase 3 study to compare the efficacy of arfolitixorin versus leucovorin incombination with 5-fluorouracil oxaliplatin and bevacizumab in patients with advanced colorectal cancer
    LEAD INVESTIGATOR: Dr Kate Mahon
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH13.015 AG0407GR
    SUMMARY:A randomised phase II/III trial of operative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer ( TOP GEAR : Trial Of Posteoperative therapy for Gastric and Esophagogastic junction AdenocaRcinoma)
    LEAD INVESTIGATOR:Dr Regina Tse
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.040 THOR
    SUMMARY: A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations.
    LEAD INVESTIGATOR: A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.016 INOVATe
    SUMMARY: Individualised Ovarian Cancer treatment through Integration of Genomic Pathology into Multidisciplinary Care.
    Intensive molecular testing on primary tumours, samples collected at relapse (ascites and biopsies) and circulating tumour DNA. Genomic biomarkers to predict treatment response will be assessed and molecular testing will be used to assist in the selection of patients for clinical trials of targeted agents. Patients will be separately consented for any HREC-approved trial for which they are found to be eligible.
    LEAD INVESTIGATOR: Dr Philip Beale
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.010 SOLACE 2
    SUMMARY: A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects” SOLACE 2
    LEAD INVESTIGATOR: Dr Philip Beale
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.040 MK7902-001
    SUMMARY: A Phase 3 randomised, open label study of pembrolizumab (MK3475) plus lenvatinib (E7080/MK-7902) versus chemotherapy for first line treatment of advansed or recurrent Endometrial Carcinoma (LEAP-001)
    LEAD INVESTIGATOR: Dr Michelle Harrison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH14.021 ANZUP 1302
    SUMMARY:  Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor-risk metastatic germ cell tumours (P3BEP Trial)
    LEAD INVESTIGATOR:  A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.021 TIGER
    SUMMARY:  A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
    LEAD INVESTIGATOR: A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.018 PSI 617-101
    SUMMARY: Phase 1b/2, Multicenter, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ST-617 for the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for Head and Neck Cancer’
    LEAD INVESTIGATOR: Dr Mun Hui
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria.
    REFER A PATIENT: Click here

 

  • TRIAL REFERENCE:  LH19.026 MK3475-630
    SUMMARY: Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advances Cutaneous Squamous Cell Carcinoma
    LEAD INVESTIGATOR: Dr Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here

 

  • TRIAL REFERENCE:  LH20.015 MK-1454
    SUMMARY: A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination with IV Pembrolizumab vs IV Pembrolizumab Monotherapy
    LEAD INVESTIGATOR: Dr Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here

 

  • TRIAL REFERENCE:  LH20.020 JG-MC-JZJB  LIBRETTO 531
    SUMMARY: A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
    LEAD INVESTIGATOR: Dr Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here

 

  • TRIAL REFERENCE:  LH20.038 MK7902-010 LEAP-010
    SUMMARY: A Phase 3 randomised placebo controlled double blind clinical study of pembrolizumab and lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervantion in a PD-L1 selected carconoma (R/M HNSCC) (LEAP-101)
    LEAD INVESTIGATOR: Dr Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here

 

  • TRIAL REFERENCE:  LH14.014 Prime Meso
    SUMMARY: The identification of predictive and prognostic factors in malignant pleural mesothelioma and prognostic factors undergoing chemotherapy
    LEAD INVESTIGATOR: Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.019 ENRICH
    SUMMARY: Embedding Research (and Evidence) in Cancer Healthcare (EnRICH)
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.050 APG 1252
    SUMMARY: A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) or Other Solid Tumors
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.058 AMG 757
    SUMMARY: A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer’ 20160323
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.060 MK 3475-598
    SUMMARY: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.024 MK3475-789
    SUMMARY: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
    LEAD INVESTIGATOR: Prof Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.025 BO40336 (ALINA)
    SUMMARY: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
    LEAD INVESTIGATOR: Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.017 61186372EDI1001
    SUMMARY: A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMET Anitbody, in Subjects with Advanced Non-Small Cell Lung Cancer
    LEAD INVESTIGATOR: Prof Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.039 MK7902-006-01 (E7080-G000-315)
    SUMMARY: A Phase 3 randomised, placebo controlled study to evaluate the safety and efficacy of pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK3475) with or without Lenvatinib (E74080/MK7902) as First-line intervantion in participants with metastatic nonsquamous non-small cell lung cancer (LEAP-006)
    LEAD INVESTIGATOR:Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.055 CA207-77T
    SUMMARY: A phase 3 randomised, double-blind study of neoadjuvant chemotherapy plus nivolumab versus neoadjuvant chemotherapy plus placebo, followed by surgical resection and adjuvant treatment with nivolumab or placebo for participants with resectable stage II-IIIB Non small cell lung cancer
    LEAD INVESTIGATOR:Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.056 rAD-IFN-MM-301 INFINITE
    SUMMARY: A Phase 3 open label randomised parallel group study to evaluate the efficacy & safety of intrapleural administration of Adenovirus-delivered Interferon Alpha-2b (rAD-IFN) in combination with Celecoxib & gemcitabine in Patients with malignant Pleural Mesothelioma
    LEAD INVESTIGATOR:Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.061 D4194R00005
    SUMMARY: PACIFIC Real World: First retrospective real-world data on unresectable stage III NSCLC Patients treated with durvalumab after chemoradiotherapy
    LEAD INVESTIGATOR:Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.019 LIBRETTO 431 LOXO-292 J2G-MC-JZJC
    SUMMARY: A multicentre randomised open label phase 3 trial comparing LOXO 292 to platinum based pemetrexed therapy with or without pembrolizumab as initial treatment of advanced metastatic RET fusion positive non small cell lung cancer
    LEAD INVESTIGATOR:Dr Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.021  AMG 510 CodeBreak 200
    SUMMARY: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously
    Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
    LEAD INVESTIGATOR:Dr Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.022 GO41767 SKYSCRAPER-02
    SUMMARY: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab Plus Carboplatin And Etoposide With Or Without Tiragolumab (Anti-Tigit Antibody) In Patients With Untreated Extensive-Stage Small Cell Lung Cancer.
    LEAD INVESTIGATOR:Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.023 AMG 510 BIO MARKER – 20190294
    SUMMARY: AMG510 A Non-Interventional Biomarker Study on the Molecular Evaluation of Archival Tumour Tissue in subjects with Non-Small Cell Lung Cancer.
    LEAD INVESTIGATOR:Dr Michael Boyer
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.051
    SUMMARY: 1336.11_An open label phase Ib dose finding study of BI 836880 in combination with BI754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors.
    LEAD INVESTIGATOR:Dr Hao-wen SIm
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.052 FLAURA 2
    SUMMARY: A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer
    LEAD INVESTIGATOR:Dr Hao-wen Sim
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.064 MeRmaiD-1 D910LC00001
    SUMMARY: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)’
    LEAD INVESTIGATOR:Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.030 MASTERPLAN
    SUMMARY: MASTERPLAN: A randomized phase II study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
    LEAD INVESTIGATOR: Dr Leily Grezaei
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.031 LEEP
    SUMMARY: A Randomised controlled Phase II trial of the pharmacodynamic effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.003 JPCM_Prostate
    SUMMARY: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of  Abiraterone Acetate plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostrate Cancer
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.005  AMG 160
    SUMMARY: A Phase 1 Study evaluating the Safety ,Tolerability, Pharmacokinteics and Efficacy of Prostate Specific Membrane Antigen Half-Lie Extended Bispecific T-cell Engager AMG 160 in subjects with metastatic Castration-resistant Prostate Canver
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.022 C3441021
    SUMMARY: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Background Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With DNA Damage Repair Deficiencies
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.037 PRINCE
    SUMMARY: Phase Ib/II study of radionuclide 177 Lutetium-PSMA 617 Therapy in combination with pembrolizumab for Treatment of metastatic resisrtant Prostate Cancer (mCRPC)
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.063 AMG 509 20180146
    SUMMARY: A Phase 1 study evaluating the safety , Tolerability, pharmacokinetics and efficacy of AMG 509 in subjects with metastatic Castration-resistant prostate cancers
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.025 MK3475-991-001
    SUMMARY: Phase 3, Randomized, Double-blind Trial of Pembrolizumab Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.045 CA209-933ISR
    SUMMARY: Nivolumab in renal transplant recipients with poor prognosis cancers – a safety study.
    LEAD INVESTIGATOR: Prof Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.038 EZH-202
    SUMMARY: Clinical Study No. EZH-202, A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
    LEAD INVESTIGATOR: David Thomas
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.037 MOST Sub Study 10
    SUMMARY: Single arm, open label, singal seeking, phase Iia trial of the activity of eribulin in patients with advanced CD31 positive angiosarcoma and selected CD31 positive sarcomas.33
    LEAD INVESTIGATOR: Dr Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.023 SU2C-SARC-032
    SUMMARY: SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
    LEAD INVESTIGATOR: A/Prof Angela Hong
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.019 rECCUr
    SUMMARY: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
    LEAD INVESTIGATOR: Dr Vivek Bhadri
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.016 CAMPRIRE JAAA
    SUMMARY: CAMPFIRE: Children’s and Young Adult Master Protocol for Innovative Pediatric Research
    LEAD INVESTIGATOR: Dr Vivek Bhadri
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.032 E7080-G000-230 OLIE
    SUMMARY: A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE)
    LEAD INVESTIGATOR: Dr Vivek Bhadri
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.005 MK-3475-158
    SUMMARY: Clinical Study No. MK-3475-158 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
    LEAD INVESTIGATOR: Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.037 MOST Sub Study 9 – PTCH1 or SMO mutations
    SUMMARY: Single arm, open label, signal seeking phase Iia trial of the activity of vismodegib in patients with tumours harbouring PTCH1 or SMO mutations
    LEAD INVESTIGATOR: DR Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.050 APG 1252
    SUMMARY: A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) or Other Solid Tumors
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.053 MK7684-001
    SUMMARY: A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumours
    LEAD INVESTIGATOR: Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.058 AMG 757
    SUMMARY: A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer’ 20160323
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.021 TIGER TICE
    SUMMARY: A randomised Phase III trial comparing conventional dose chemotherapy using paclitaxel, ifosfamide & cisplatin (TIP) with high dose chemptherapy using mobilising paclitaxel plus ifosfamide followed by high dose carboplatin & etoposide (TI-CE) as first salvage treatment in relapsed or refactory germ cell tumors
    LEAD INVESTIGATOR: Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.045 CA209-933 ISR – CALHAN
    SUMMARY: PD-1 blockade in renal transplant patients with poor prognosis cancer and minimising risk organ rejection using comprehensive immune monitoring and screening techniques as a safetystudy – SHORT TITLE – Nivolumab inrenal transplant recipients with cancer
    LEAD INVESTIGATOR: Dr Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.004 FPT155-001
    SUMMARY: A Phase 1a/1b Study of FPT155 in patients with advanced Solid Tumors
    LEAD INVESTIGATOR: Dr Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.005  AMG 160
    SUMMARY: A Phase 1 Study evaluating the Safety ,Tolerability, Pharmacokinteics and Efficacy of Prostate Specific Membrane Antigen Half-Lie Extended Bispecific T-cell Engager AMG 160 in subjects with metastatic Castration-resistant Prostate Canver
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.008 MK3475-587
    SUMMARY: A Multi-center, Open label, Phase III Extension Trial to Study the Long-term   Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
    LEAD INVESTIGATOR: Dr Catriona McNeil
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.014 CPI-006-01
    SUMMARY: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CP-I006. As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
    LEAD INVESTIGATOR: Dr Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.017 61186372EDI1001
    SUMMARY: A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMET Anitbody, in Subjects with Advanced Non-Small Cell Lung Cancer
    LEAD INVESTIGATOR: Prof Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.018 PSI 617-101
    SUMMARY: Phase 1b/2, Multicenter, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ST-617 for the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for Head and Neck Cancer’
    LEAD INVESTIGATOR: Dr Mun Hui
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria.
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.024 AMG 404
    SUMMARY: A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients with Advanced Solid Tumors’
    LEAD INVESTIGATOR: Dr Mun Hui
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.026 MK3475-630
    SUMMARY: Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advances Cutaneous Squamous Cell Carcinoma
    LEAD INVESTIGATOR: Dr Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.037 PRINCE
    SUMMARY: Phase Ib/II study of radionuclide 177 Lutetium-PSMA 617 Therapy in combination with pembrolizumab for Treatment of metastatic resisrtant Prostate Cancer (mCRPC)
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.038 CS3002-001
    SUMMARY: A Phase 1 open label, multiple dose, dose escalation and expansion study to investigate the safety, tolerability, pharmacokinetics & anti tumour activities of CS3002, A CDK4/6 inhibitor, in subjects with advanced solid tumours
    LEAD INVESTIGATOR: Dr Mun Hui
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.045 TKI- TPX-005 (TRIDENT-1)
    SUMMARY: A Phase 1/2 open label multi centre first in human study of the safety, tolerability, pharmacokinetics and anti tumour activity of TPX-005 in patients with advanced solid tumours harbouring ALK, ROS1 or NTRK1-3 rearrangments TRIDENT-1
    LEAD INVESTIGATOR: Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.048 MG010  Metagone  SUCCEED
    SUMMARY: A Phase I/II open label multi-centre study to assess the safety tolerability and efficacy of MG010 in combination with sorafenib in subjects with solid tumours who have failed existing treatments
    LEAD INVESTIGATOR: Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.049 BGB-900-105
    SUMMARY: Phase 1/1b investigating tolerability, pharmacokinetics & preliminary Antitumour Activity of Anti TIGIT Monoclonal Antibody Tislelizumab (BGB-A317) in patients with unresectable Locally Advanced or metastatic solid tumours
    LEAD INVESTIGATOR: Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.057 CC95251 SIRPa
    SUMMARY: Phase 1 open label dose finding study of CC-95251, a monoclonal antibody directed against SIRPa Alone and in combination with cetuximab in subjects with advanced solid and hematologic cancers
    LEAD INVESTIGATOR: Dr Lisa Hovarth
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.062 CERPASS
    SUMMARY: A randomised controlled open label Phase 2 study of cemiplimab as a single agent & in combination with RP1 in patients with Advanced Cutaneous Squamous Cell Carcinoma
    LEAD INVESTIGATOR: DR Jenny Lee
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.063 AMG 509 20180146
    SUMMARY: A Phase 1 study evaluating the safety , Tolerability, pharmacokinetics and efficacy of AMG 509 in subjects with metastatic Castration-resistant prostate cancers
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.003 LIBRETTO 201 LOXO RET
    SUMMARY: A multicenter expanded access program (EAP) for the treatment of patients with locally advanced or metastatic solid tumours with rearranged transfection (RET) Activation LOBRETTO 201
    LEAD INVESTIGATOR: Dr Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.012 RAGNAR
    SUMMARY: A Phase 2 study of Erdafitinib in subjects with advanced solid tumours and EGFR Gene Alterations
    LEAD INVESTIGATOR: Dr Alison Zhang
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.013  M19-345 ABBV-151
    SUMMARY: A Phase 1 first in human multi centre open label dose escalation study to determine the safety tolerability pharmacokinetics and RP2D of ABBV-151 as a single agent and in combination with ABBV-181 in subjects with locally advanced or metastatic solid tumours
    LEAD INVESTIGATOR: Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.014 SQ3370
    SUMMARY: A Multicentre Phase 1 open label study of SQ3370 inpatients with advanced solid tumours
    LEAD INVESTIGATOR: Dr Vivek Bhadri
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.016 CAMPRIRE JAAA
    SUMMARY: CAMPFIRE: Children’s and Young Adult Master Protocol for Innovative Pediatric Research
    LEAD INVESTIGATOR: Dr Vivek Bhadri
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.039 XL184-021
    SUMMARY: XL184 A Phase 1B Dose Escalation study of Cabozantinib administered alone or in combination with Atezolizumab to subjects with loally advanced or metastatic solid tumours
    LEAD INVESTIGATOR: Dr Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.051
    SUMMARY: 1336.11_An open label phase Ib dose finding study of BI 836880 in combination with BI754091 to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors.
    LEAD INVESTIGATOR:Dr Hao-wen SIm
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.057 C0541001
    SUMMARY: A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06804103 IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE SOLID TUMORS
    LEAD INVESTIGATOR: Dr Mun Hui
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.059 CA209-8TT
    SUMMARY: Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab
    LEAD INVESTIGATOR: Dr Catriona McNeil
    ADDITIONAL INFORMATIONInclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.040 THOR – JNJ 42756493
    SUMMARY: Clinical Study JNJ42756493 : a Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene
    LEAD INVESTIGATOR: Professor Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH14.014 Prime Meso
    SUMMARY: The identification of predictive and prognostic factors in malignant pleural mesothelioma and prognostic factors undergoing chemotherapy
    LEAD INVESTIGATOR: Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.037 MOST Sub Study 9 – PTCH1 or SMO mutations
    SUMMARY: Single arm, open label, signal seeking phase Iia trial of the activity of vismodegib in patients with tumours harbouring PTCH1 or SMO mutations
    LEAD INVESTIGATOR: DR Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.037 MOST Sub Study 10
    SUMMARY: Single arm, open label, singal seeking, phase Iia trial of the activity of eribulin in patients with advanced CD31 positive angiosarcoma and selected CD31 positive sarcomas.33
    LEAD INVESTIGATOR: DR Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.003 NUTMEG
    SUMMARY: A Randomised Phase II Study of NivIUmab and TeMozolomide alone in newly diagnosed Elderly patients with Glioblastoma (NUTMEG)
    LEAD INVESTIGATOR: Dr John Simes
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.041 TROG 15.02 ROAM
    SUMMARY: Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled tiral (ROAM)
    LEAD INVESTIGATOR: Dr Nitya Patanjali
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.006 WEHI
    SUMMARY: The WEHI Stafford Rare Cancer Program – Discovery of novel therapeutic targets within the biology of rare cancers
    LEAD INVESTIGATOR: DR Michelle Harrison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.014 CPI-006-01
    SUMMARY: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CP-I006. As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
    LEAD INVESTIGATOR: Dr Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH20.011 CARE
    SUMMARY: Cannabinoids for symptomcontrol in advanced cancer, open label prospective clinical trials in NSW
    LEAD INVESTIGATOR: Dr Judith Lacey
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search